Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Health SARS-CoV-2 Test Receives CE-IVD Mark

NEW YORK – Yourgene Health said on Monday that its Clarigene SARS-CoV-2 in vitro diagnostic kit has received the CE-IVD mark for diagnostic use.

The IVD version of the test will be used in Yourgene's high-throughput COVID-19 service lab in Manchester, UK. The test is an RT-qPCR assay, which detects the presence of SARS-CoV-2 viral RNA. It uses two viral RNA targets, nucleocapsid gene N and envelope gene E, which are specific to COVID-19, preventing cross reaction with other coronaviruses, Yourgene said.

In clinical validation, the test achieved greater than 99.9 percent accuracy with no false-positive or false-negative results, it added, while additional studies demonstrated 100 percent repeatability data and an average of greater than 99.7 percent reproducibility.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.